Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 213038
Company: LAURUS
Company: LAURUS
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE | 400MG;300MG;300MG | TABLET;ORAL | Prescription | AB | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
05/14/2020 | ORIG-1 | Approval | STANDARD |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213038Orig1s000ltr.pdf |
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL; 400MG;300MG;300MG
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE | 400MG;300MG;300MG | TABLET;ORAL | Prescription | No | AB | 213038 | LAURUS |
SYMFI LO | EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE | 400MG;300MG;300MG | TABLET;ORAL | Prescription | Yes | AB | 208255 | MYLAN |